Nivarta, Inc. is a discovery stage company located in Cambridge, Massachusetts, USA that is focused on diabetes and Dercum’s disease. The diabetes program aims at translating the anti-diabetic effects of surgery into therapeutics. Towards this goal, we have recently identified a gene that is central to diabetes remission and are currently setting up a HTS to select inhibitors. In the near term, we are looking to raise capital needed to generate data for IND filing. In addition, we are also looking for partners who might be interested in co-development of the molecule through pre-clinical and clinical phases.
Towards treating Dercum’s disease that is characterized by the formation of painful lipomas under the skin, we are developing a protein that causes fat lipolysis and shrinks the lipomas when injected subcutaneously. Since there are no drugs available to treat this rare disease, there is a significant unmet need. Presently, we are working on obtaining an orphan disease status and filing patents to secure the use of the protein for Dercum’s indication. In two years, we anticipate to have a proof-of-concept in man.